Jasper Therapeutics Won Clearance for Initiation of its Phase 1b/2a BEACON Study of Subcutaneous Briquilimab in CSU, Phase 1b/2a SPOTLIGHT Study, Initiated a Phase 1 Trial of Briquilimab as Second-Line Therapy in Subjects with Myelodysplastic Syndromes

Author: Benzinga Newsdesk | March 04, 2024 08:39am

Highlights for 2023 and Recent Weeks

• Successfully completed an underwritten offering of 3,900,000 shares of its common stock for gross proceeds of approximately $50 million in February 2024, which extends Jasper's cash runway through the third quarter of 2025.
  
  
   
• Obtained regulatory clearance in the US and EU for initiation of its Phase 1b/2a BEACON study of subcutaneous briquilimab in CSU. The BEACON study is a dose escalation trial evaluating repeat doses of subcutaneous briquilimab in adult CSU patients who remain symptomatic after treatment with, or who cannot tolerate, omalizumab, and is currently enrolling approximately 40 patients at sites in the US and EU. As of March 3rd, 2024, Jasper had opened 15 clinical sites across the U.S. and EU, and is currently enrolling in the second cohort of the study. Jasper expects to report initial data from at least the first four cohorts of the study in the third quarter of 2024.
  
  
   
• Obtained regulatory approval for initiation of its Phase 1b/2a SPOTLIGHT study evaluating single doses of subcutaneous briquilimab in adult CIndU patients. Jasper expects to conduct the study across four clinical sites in the EU and has activated three sites to date.
  
  
   
• Initiated a Phase 1 trial of briquilimab as second-line therapy in subjects with lower to intermediate risk myelodysplastic syndromes (LR-MDS). As of March 3, 2024, Jasper had fully enrolled the first two dose escalation cohorts and is enrolling in the third cohort. Jasper expects to report initial data from this study by mid-year 2024.
  
  
   
• Presented preclinical briquilimab data at the AAAAI 2024 Annual Meeting from studies utilizing Jasper's proprietary c-Kit Mouse™ in a variety of indications, demonstrating the potential of briquilimab to mitigate the likelihood of severe allergic reaction and anaphylaxis.

Posted In: JSPR